AI Earnings Predictions for Senseonics Holdings Inc. (SENS)

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786363765.c9cce2c6

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99.1

2 sens-20260507xex99d1.htm

EX-99.1

​

​

Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results

​

Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year

​

Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M)

​

Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe

​

Raised $100M+ in equity and debt financing to support commercial strategy and pipeline

​

GERMANTOWN, MD.—May 7, 2026 (BUSINESS WIRE)-- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update.

​

Recent Highlights & Accomplishments

​

●Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year

●Continued commercial momentum for Eversense 365 in the US, primarily driven by direct-to-consumer marketing efforts, with DTC new patient adds up nearly 100% year-over-year.

●Achieved gross margin of 59% in Q1, an increase of 35% year-over-year, reflecting benefits from the commercial transition, scale and manufacturing efficiencies

●Initiated commercial launch with twiist™ to support US patient growth, with encouraging early uptake of Eversense 365 as part of an Automated Insulin Delivery (AID) system

●Currently launching Eversense 365 in Europe with first insertions in Sweden in April, following CE Mark approval in January

●Raised $92 million in growth capital through recent public offering of securities

●Amended and expanded Hercules debt facility to further strengthen balance sheet

​

Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics said, “This was our first quarter as a fully-integrated commercial organization in the U.S., following the successful transition of the U.S. Eversense Sales and Marketing team to Senseonics. However, this wasn’t just a quarter of important strategic progress, it was a strong quarter of commercial delivery, with both revenue and gross margins exceeding our expectations. We have now secured over $100 million in equity and debt financing to continue to fund our ongoing global launch of Eversense 365 and support the continued development of our pipeline, which includes the Gemini and Freedom systems. I’m proud of the team’s ability to both adapt and deliver during a crucial evolution of our business, which is now end-to-end, gaining momentum and moving forward more ambitiously.”

​

First Quarter 2026 Results:

​

Total revenue for the first quarter of 2026 was $11.7 million compared to $6.3 million for the first quarter of 2025. U.S. revenue was $9.3 million for the first quarter of 2026 compared to $4.5 million for the first quarter of 2025, and revenue outside the U.S. was $2.4 million in the first quarter of 2026 compared to $1.8 million in the prior year period.

​

First quarter 2026 gross profit was $6.9 million compared to a gross profit of $1.5 million for the first quarter of 2025. The increase in gross profit was primarily due to higher U.S. revenues driven by continued adoption of the Eversense E365 system, higher average selling prices, and a more streamlined manufacturing and supply chain, contributing to improved margins. First quarter 2026 gross profit also included a one-time benefit of $0.5 million related to the timing of the Eversense 365 product launch in Europe.

​

First quarter 2026 research and development expenses increased by $1.3 million year-over-year to $8.6 million from $7.3 million for the first quarter of 2025. The increase was primarily driven by the new R&D project spend, along with the ramp-up of new clinical trials and increased headcount to support these activities.

​

First quarter 2026 selling, general and administrative expenses increased by $22.5 million year-over-year to $30.2 million from $7.7 million for the first quarter of 2025. The increase was primarily driven by higher sales and marketing and general and administrative expenses associated with the U.S. commercial integration and the transition of Eversense commercialization and distribution, including increased personnel, transition support, direct-to-consumer marketing, and other operational costs.

​

Net loss was $32.3 million, or a $0.71 loss per share, in the first quarter of 2026 compared to net loss of $14.3 million, or a $0.40 loss per share, in the first quarter of 2025. Net loss increased by $18 million primarily due to increased expenses due to the costs related to taking over the commercialization and distribution of Eversense.

​

Cash, cash equivalents and investments were $64.6 million and outstanding indebtedness was $35.2 million.

​

Full Year 2026 Financial Outlook

​

Senseonics now expects full-year 2026 global net revenue to be approximately $60 – $64 million, representing year-over-year growth of

EX-99.1

5 tm2613286d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

GERMANTOWN, MD – (GLOBE NEWSWIRE) – April 30, 2026 – Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and, to certain investors, pre-funded warrants to purchase its common stock in lieu thereof. In connection with the proposed offering, Senseonics also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares offered in the public offering. All of the securities to be sold in the proposed offering will be offered by Senseonics. The pre-funded warrants will not be listed on any securities exchange.

TD Cowen and Barclays are acting as joint book-running managers and

Mizuho and Lake Street are acting as bookrunners for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

The proposed offering is being made pursuant to a “shelf” registration statement on Form S-3, including a base prospectus (File No. 333-289306) that was originally filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025 and became effective on August 18, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained, when available, by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

Senseonics intends to use the net proceeds from the public offering to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes.

Before investing in the offering, you should read the preliminary prospectus supplement and related prospectus for the offering, including the documents incorporated by reference therein, that Senseonics has filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development, manufacturing and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, the size of the proposed offering; Senseonics’ expectations about the completion and timing of the proposed offering and anticipated use of proceeds from the proposed offering; and Senseonics’ expectations with respect to granting the underwriters a 30-day option to purchase additional shares. The words “expects,” “potential,” “proposed,” “may,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to Senseonics’ inability, or the inability of underwriters, to satisfy the conditions to closing for the proposed offering; uncertainties relating to the current ec